Impact BioMedical Inc. (IBO) Revenue History
Annual and quarterly revenue from 2017 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
IBO Revenue Growth
IBO Revenue Analysis (2017–2024)
As of May 8, 2026, Impact BioMedical Inc. (IBO) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2025) recorded $0 in revenue.
Looking at the longer-term picture, IBO's historical revenue data shows a 3-year CAGR of +259.9%. The company achieved its highest annual revenue of $2.3 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including NVAX (-52.5% YoY), VXRT (+726.7% YoY), and OCGN (+8.8% YoY). Compare IBO vs NVAX →
IBO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IBOCurrent | $0 | - | - | 23.7% | |
 NVAX | $1.1B | -52.5% | +118.8% | 50.1% | |
 VXRT | $237M | +726.7% | +125.8% | 7.6% | |
 OCGN | $4M | +8.8% | +152.5% | -1425.7% | |
 ADMA | $510M | +11.0% | +64.6% | 37.5% |
IBO Historical Revenue Data (2017–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $2.3M | - | $2.3M | 100.0% | $552K | 23.7% |
| 2023 | $0 | -100.0% | $0 | - | $-4,028,000 | - |
| 2022 | $50K | +0.0% | $50K | 100.0% | $-3,404,000 | -6808.0% |
| 2021 | $50K | - | $50K | 100.0% | $-3,404,000 | -6808.0% |
| 2020 | $0 | - | $0 | - | $-1,141,013 | - |
| 2019 | $0 | - | $0 | - | $-680,025 | - |
| 2018 | $0 | - | $0 | - | $-33,861 | - |
| 2017 | $0 | - | $0 | - | $64K | - |
See IBO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IBO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IBO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIBO — Frequently Asked Questions
Quick answers to the most common questions about buying IBO stock.
Is IBO's revenue growth accelerating or slowing?
IBO TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is IBO's long-term revenue growth rate?
Impact BioMedical Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is IBO's revenue distributed by segment?
IBO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2024 are available for download. Segment mix reveals concentration and diversification trends.